Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 11/20 | 0.54 |
| ▸ | CA2 | P00918 | 11/20 | 0.54 |
| ▸ | CA12 | O43570 | 5/20 | 0.54 |
| ▸ | CA9 | Q16790 | 5/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | NQO2 | P16083 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3244228 | 1.00 | CA1 (0.54) | CA1CA2CA12CA9TDP1 | |
| SCHEMBL382478 | 0.91 | NQO2 (0.51) | CA1CA2CA12CA9TDP1 | |
| SCHEMBL25263115 | 0.86 | CA1 (0.49) | CA1CA2CA12CA9NQO2 | |
| SCHEMBL21070849 | 0.86 | CA1 (0.49) | CA1CA2CA12CA9NQO2 | |
| SCHEMBL29040412 | 0.81 | CA1 (0.48) | CA1CA2CA12CA9TDP1 | |
| SCHEMBL597639 | 0.81 | CA1 (0.48) | CA1CA2CA12CA9TDP1 | |
| SCHEMBL28899596 | 0.81 | CA1 (0.48) | CA1CA2CA12CA9TDP1 | |
| SCHEMBL29040477 | 0.81 | CA1 (0.48) | CA1CA2CA12CA9TDP1 | |
| SCHEMBL29040418 | 0.81 | CA1 (0.48) | CA1CA2CA12CA9TDP1 | |
| SCHEMBL28468535 | 0.81 | CA1 (0.48) | CA1CA2CA12CA9TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269943-A1 | RADIOLABELED ANNEXINS | UNIVERSITY OF WASHINGTON (US) | 2011-11-03 | — | — | US | disclosed |
| US-7744853-B2 | Radiolabeled annexins | PONIARD PHARMACEUTICALS, INC. (US) | 2010-06-29 | — | — | US | disclosed |
| US-7115248-B2 | Radiolabeled annexins | NEORX CORPORATION (US) | 2006-10-03 | — | — | US | disclosed |
| US-20060029545-A1 | Radiolabeled annexins | NEORX CORPORATION, REGENTS OF THE UNIVERSITY OF MICHIGAN | 2006-02-09 | — | — | US | disclosed |
| US-6908903-B1 | Cluster clearing agents | ALETHEON PHARMACEUTICALS, INC. (US) | 2005-06-21 | — | — | US | disclosed |
| US-20050036948-A1 | Radiolabeled annexins | NEORX CORPORATION (US) | 2005-02-17 | — | — | US | disclosed |
| EP-1426062-A2 | Radiolabeled annexins | NEORX CORPORATION (US) | 2004-06-09 | — | — | EP | disclosed |
| EP-0918547-B1 | RADIOLABELED ANNEXINS | NEORX CORP (US) | 2004-03-10 | — | — | EP | disclosed |
| US-20030220233-A1 | Radiolabeled annexins | NEORX CORPORATION | 2003-11-27 | — | — | US | disclosed |
| US-20020137672-A1 | Radiolabeled annexins | KASINA SUDHAKAR (US) | 2002-09-26 | — | — | US | disclosed |
| US-6172045-B1 | COMPLEX CONTAINING 1-DESOXY-1-THIO-N-ACETYLGALACTOSAMINE | NEORX CORPORATION | 2001-01-09 | — | — | US | disclosed |
| EP-0914042-A4 | CLUSTER CLEARING AGENTS | NEORX CORP (US) | 2000-10-25 | — | — | EP | disclosed |
| US-5968477-A | IMAGING AGENTS WITH SULFHYDRYL GROUPS AND HEXOSE GROUPS | NEORX CORPORATION (US) | 1999-10-19 | — | — | US | disclosed |
| EP-0918547-A2 | RADIOLABELED ANNEXINS | NEORX CORPORATION (US) | 1999-06-02 | — | — | EP | disclosed |
| EP-0914042-A1 | CLUSTER CLEARING AGENTS | NEORX CORPORATION (US) | 1999-05-12 | — | — | EP | disclosed |
| WO-1997046098-A9 | CLUSTER CLEARING AGENTS | — | 1998-08-06 | — | — | WO | disclosed |
| WO-1998004294-A2 | RADIOLABELED ANNEXINS | NEORX CORPORATION (US) | 1998-02-05 | — | — | WO | disclosed |
| WO-1997046098-A1 | CLUSTER CLEARING AGENTS | NEORX CORPORATION (US) | 1997-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060029545-A1 | Radiolabeled annexins | ANXA11, ANXA1, ANXA3 | CA1 1557/4885CA2 2516/4885CA12 1214/4885 |
| US-20050036948-A1 | Radiolabeled annexins | ANXA11, ANXA1, ANXA3 | CA1 1557/4885CA2 2516/4885CA12 1214/4885 |
| US-20110269943-A1 | RADIOLABELED ANNEXINS | ANXA11, ANXA1, ANXA3 | CA1 1557/4885CA2 2516/4885CA12 1214/4885 |
| US-20020137672-A1 | Radiolabeled annexins | ANXA11, ANXA1, ANXA3 | CA1 1557/4885CA2 2516/4885CA12 1214/4885 |
| US-20030220233-A1 | Radiolabeled annexins | ANXA11, ANXA1, ANXA3 | CA1 1557/4885CA2 2516/4885CA12 1214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.